

Title	Impact of vitamin D on gene expression in Atlantic salmon skin
Authors	Taylor, Lewis D.;Gorman, Courtney E.;Egan, Fintan;Ruane, Neil M.;McGinnity, Philip;Hulsey, C. Darrin
Publication date	2026-05-18
Original Citation	Taylor, L D, Gorman, C E, Egan, F, Ruane, N M, McGinnity, P & Hulsey, C D 2026, 'Impact of vitamin D on gene expression in Atlantic salmon skin', PLOS ONE, vol. 21, no. 5, e0349197, pp. 1-14. https://doi.org/10.1371/journal.pone.0349197
Type of publication	Article (Peer reviewed)
Link to publisher's version	10.1371/journal.pone.0349197
Rights	cc_by
Download date	2026-08-26 20:53:36
Item downloaded from	https://hdl.handle.net/10468/19128

RESEARCH ARTICLE


Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls

Julia Corinna Putz¹*, Marilena Wilding¹*, Sonja Lackner^{1,2*}, Martin Narrath¹, Daria Schlotmann¹, Marie-Therese Sallmutter¹, Jasmin Tatzer¹, Andreas Brandstätter¹, Julia Deborah Lang¹, Sandra Holasek², Julian Wenninger¹, Mary I. Butler³, Susanne Bengesser⁴, Lena Gruber¹, Andreas Baranyi⁴, Jolana Wagner-Skacel¹, Sabrina Mörk¹

1 Department of Psychiatry, Psychosomatics and Psychotherapeutic Medicine, Division of Medical Psychology, Psychosomatics and Psychotherapy, Medical University of Graz, Graz, Styria, Austria, **2** Division of Immunology, Otto Loewi Research Center, Medical University of Graz, Graz, Styria, Austria, **3** Department of Psychiatry and Neurobehavioral Science, University College Cork, Cork, Munster, Ireland, **4** Department of Psychiatry, Psychosomatics and Psychotherapeutic Medicine, Division of Psychiatry and Psychotherapeutic Medicine in Graz, Graz, Styria, Austria

* These authors contributed equally to this work and share first authorship.

* sonja.lackner@medunigraz.at



OPEN ACCESS

Citation: Putz JC, Wilding M, Lackner S, Narrath M, Schlotmann D, Sallmutter M-T, et al. (2026) Do probiotics modulate dietary intake? Pilot data from a randomized controlled sub-study of the ProBioHRV clinical trial in patients with depression and healthy controls. PLoS One 21(6): e0350801. <https://doi.org/10.1371/journal.pone.0350801>

Editor: Cheung Kenneth Chat Pan, Hong Kong Baptist University, HONG KONG

Received: October 29, 2025

Accepted: May 12, 2026

Published: June 23, 2026

Copyright: © 2026 Putz et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data availability statement: All relevant data for this study are publicly available from the OSF repository (<https://osf.io/5crbj>).

Funding: - S. M. - Projekt-ID: 6649 - Allergosan - <https://www.allergosan.com/at/> - No.

Abstract

Background

The gut microbiome plays a central role in human health and is strongly influenced by diet. Probiotics can beneficially modulate the microbiome and, through the gut–brain axis, may affect mood, appetite, and food preferences. This randomized controlled trial examined whether three months of probiotic supplementation could alter dietary intake in individuals with major depression (*MD*) and healthy controls (*HC*).

Methods

In this double-blind, placebo-controlled trial, 53 participants (23 with *MD*, 30 *HC*) received either a multi-strain probiotic or placebo twice daily for three months. Dietary intake was assessed at baseline and three follow-ups using the Vienna Food Record (VFR). Nutritional data were analyzed with nut.s® software and evaluated using mixed ANOVAs for repeated measures. These analyses represent additional data collected within the framework of the ProBioHRV study.

Results

Changes across dietary measures were generally small, with only a limited number reaching statistical significance. Significant three-way interactions (*time* × *intervention* × *diagnosis*) emerged for vitamin D intake, dietary variety, folic acid, and diversity.

Publication costs for this article were funded by Land Steiermark, Abteilung 12, Wirtschaft, Tourismus, Wissenschaft und Forschung.

Competing interests: The authors have declared that no competing interests exist.

In *HC*, probiotic supplementation was associated with higher vitamin D intake after one week, while in *MD*, a similar increase was observed after three months (trend level, $p = .058$). Conversely, participants receiving probiotics showed lower dietary variety and diversity scores at several time points. Across all time points, folic acid intake was lower in *MD* compared to *HC*, independent of intervention.

Conclusion

Probiotic supplementation did not produce consistent changes in nutrient intake but showed exploratory, time- and group-dependent patterns for selected measures, including vitamin D intake and dietary variety and diversity. Given the pilot nature of the study, these findings are descriptive and hypothesis-generating. Larger, well-powered studies with objective nutritional and microbiome measures are required.

Introduction

Gut microbiome and dietary intake

The human gut harbors trillions of microorganisms, including prokaryotes, archaea, and eukaryotes, far exceeding the number of humans who have ever lived [1–3]. The intestinal microbiota plays a key role in energy extraction, vitamin synthesis (e.g., vitamin B12), bile acid metabolism, and dietary fiber breakdown via fermentation, hydrolysis, and deconjugation [4–6]. Microbial composition is dynamic and influenced by factors like age, sex, medications, environmental exposures, geographical origin, diseases, and notably diet [7–10]. Diets low in fiber and high in processed foods, sugars, fats, and animal proteins – typical of the Western diet – have been found to reduce gut microbial diversity [11,12] whereas fiber-rich diets like the Mediterranean diet seem to promote microbial diversity and anti-inflammatory stability [13,14].

The gut microbiome is highly responsive to dietary changes, with shifts observed after only one day on a high-fat diet in mice [15]. In humans, Western diets decrease beneficial bacteria like *Bifidobacteria* and *Eubacteria* [12,16,17], while Mediterranean diets enrich beneficial microbial populations and potentially counteract obesity and inflammation [13,14,18].

Alterations in gut microbiota composition are associated with obesity, often reflected in changes in the *Firmicutes/Bacteroidetes* ratio [19–21]. Some studies found a lower microbial diversity in obese individuals [19,22], although findings are not entirely consistent [19,23]. Similarly, dysbiosis has been linked to mental health conditions such as depression, bipolar disorder, autism spectrum disorder, anorexia nervosa and ADHD [24–27]. However, causal relationships remain to be fully clarified [28].

Microbiome and appetite regulation

Gut bacteria may influence appetite regulation through interactions with hormonal and metabolic pathways. Key hormones include leptin, ghrelin, and insulin, alongside microbiota-derived metabolites like short-chain fatty acids (SCFA) [29].

Leptin, secreted mainly by adipose tissue, suppresses appetite via hypothalamic signaling [30–38]. Higher gut microbial diversity is associated with better leptin signaling, while lower diversity correlates with elevated leptin levels [29,39].

Conversely, ghrelin, the “hunger hormone” stimulates appetite and energy intake [40–43], while insulin promotes satiety and regulates appetite through hypothalamic pathways [44–47]. Notably, lower gut microbiome diversity has been linked to insulin resistance [39] and alterations in energy homeostasis [46,48].

Microbial influences on food preferences and eating patterns may involve modulation of taste receptors, neurotransmitter production, hormonal pathways, and the induction of dysphoria to favor specific nutrient intakes [49]. These mechanisms highlight a potential role of the gut microbiome in appetite regulation and food choice.

Probiotics, diet and depression

Probiotics – live microorganisms offering health benefits – mainly include *Lactobacilli* and *Bifidobacteria* [50]. They are established treatments for gastrointestinal [51–53] and are increasingly studied for psychiatric disorders like depression and ADHD [27,52,54–59]. Further, probiotics have been suggested as an add-on therapy for depression in recent guidelines [60].

Importantly, probiotic intake has been associated with reductions in body weight, BMI, and appetite-related hormones such as ghrelin [61–68]. Furthermore, given the broad impact of probiotics via the gut-brain axis – such as modulation of HRV [69] and the reduction of depressive symptoms in patients with unipolar depression [54,55,57] – it would be valuable to investigate whether dietary changes also play a role in conjunction with probiotic intake. This is particularly relevant given that dietary alterations can influence the gut microbiome, and microbiome dysbiosis has been associated with psychiatric disorders such as depression [24–27]. Additionally, changes in dietary patterns have been associated with improvements in patients with depression [70]. This relationship is a central focus of the emerging field of “nutritional psychiatry,” which examines how macro- and micronutrients influence neurotransmitter synthesis and, in turn, affect the development and course of psychiatric disorders [58,70,71].

Research question and hypotheses

Building on these findings, we aimed to investigate whether daily probiotic supplementation over a period of three month influences dietary intake (i.e., the consumption of macro- and micronutrients) in individuals with major depression (MD) and healthy controls (HC).

We hypothesized that probiotic intervention would change patterns of dietary intake such as variety and diversity by modulating appetite-regulating pathways, potentially fostering healthier eating patterns and improved nutritional quality, which may contribute to both physiological well-being and mental health outcomes.

Materials and methods

Participants

The details of the study design have already been described in Mörk et al. (2025) and will therefore only be briefly summarized here [69].

All data were collected between 16 August 2021 and 27 June 2023 at the University Clinic for Psychiatry and Psychotherapeutic Medicine in Graz as part of the project “Probiotics and the gut-brain axis: Do probiotics interact with the vagus nerve?” Participants were recruited at the Department for Psychiatry and Psychotherapeutic Medicine, on social media or via the online recruitment-service Probando (www.probando.io), resulting in 86 volunteers. Due to incomplete food frequency questionnaire data, 33 participants had to be excluded from the statistical analysis, resulting in 53 participants between 18 and 67 years (see Fig 1). Participants had either a diagnosis of major depression ($n=23$; depression group, MD) or were free of psychiatric diseases ($n=30$; healthy controls, HC). Patients with MD and HC were each randomly




Fig 1. CONSORT flow chart illustrating the recruitment process and associated drop-outs. *Drop-out was due to incomplete dietary assessments.

<https://doi.org/10.1371/journal.pone.0350801.g001>

assigned to either a *probiotic* (n=25) or *placebo* (n=28) group, resulting in four condition groups. The final group sizes for analysis differ slightly due to drop-outs during the intervention period (see Table 1).

All participants underwent a structured clinical interview (M.I.N.I.-International Neuropsychiatric Interview) conducted by a trained psychiatrist or psychologist to either confirm the *MD* diagnosis or to exclude *HC* with any psychiatric diagnosis, according to the International Classification of Diseases (ICD-10) [72]. Further exclusion criteria for all participants were: suicidal tendencies, lack of consent or capacity to consent, known cardiovascular diseases, pregnancy, breastfeeding, pronounced dependence on alcohol or psychotropic substances (benzodiazepines, morphines), other severe mental or organic diseases (epilepsy, brain tumors, trauma, severe recent surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression (lupus erythematosus, HIV, multiple sclerosis), antibiotic therapy in the last month, laxative abuse, acute infections, diarrhea and gastrointestinal surgery (except appendectomy). Participants were required to not have taken probiotics in the preceding 6 months. Furthermore, they were instructed to refrain from consuming any additional probiotics during the study period. In addition, the intake of antibiotics and prebiotic supplements was an exclusion criterion. All participants provided written informed consent. Each participant was assigned an individual number, and the data were pseudonymized to prevent any identification by name. Identification of participants was possible solely by the authors, and only if required.

Table 1. Anthropometric and questionnaire data for all groups.

	Placebo (n = 28)	Probiotics (n = 25)	p	HC (n = 30)	MD (n = 23)	p	MD Probiotics (n = 11)	HC Probiotics (n = 14)	p	MD Placebo (n = 12)	HC Placebo (n = 16)	p
Sex (female)	23	16	.212	21	18	.547	9 (2)	7 (7)	.208	9 (3)	14 (2)	.624
Smoking status	4	6	.488	4	6	.300	3	3	1.000	3	1	.285
Age (years)	35.0 (25.0–53.5)	36.0 (24.0–44.5)	.475	34.5 (25.0–46.8)	36.0 (24.0–52.0)	.767	31.0 (22.0–39.0)	36.00 (26.50–49.50)	.159	44.50 (25.00–56.50)	31.00 (25.00–45.75)	.450
Weight (kg)	66.3 (59.5–75.1)	64.0 (58.6–84.0)	.708	62.4 (56.7–76.1)	68.3 (60.7–82.5)	.209	70.0 (60.7–93.0)	60.45 (56.23–75.38)	.183	67.80 (59.65–73.03)	64.15 (57.65–77.03)	.732
Height (cm)	169.54 (9.07)	170.88 (7.96)	.571	170.37 (7.69)	169.91 (9.64)	.850	170.18 (7.51)	171.43 (8.53)	.706	169.67 (11.60)	169.44 (7.01)	.949
BMI (kg/m²)	22.2 (20.4–26.1)	22.9 (20.9–27.2)	.510	21.8 (20.7–25.6)	23.6 (21.0–27.0)	.151	23.8 (21.1–30.6)	22.05 (20.78–25.64)	.109	22.96 (20.67–26.06)	21.55 (20.02–25.95)	.537
BDI (t1)	11.68 (12.34)	11.88 (12.34)	.818	4.34 (4.13)	21.13 (12.65)	<.001***	19.73 (13.99)	5.23 (4.95)	.007**	22.42 (11.77)	3.62 (3.30)	<.001***
HAMD (t1)	8.75 (10.73)	10.29 (12.01)	.342	1.83 (1.34)	19.09 (10.85)	<.001***	19.91 (11.91)	2.15 (1.34)	<.001***	18.33 (10.25)	1.56 (1.31)	<.001***

Note. Values are presented as mean (SD); non-normally distributed variables are reported as median (IQR). P-values indicate differences between the two adjacent groups to the left. Statistical significance was set at $p < .05$. ** $p < .01$; *** $p < .001$. Significant results are shown in bold.

<https://doi.org/10.1371/journal.pone.0350801.t001>

Study design

Participants had to visit the clinic at four different time points for data collection: at baseline (before the intervention; t_1), 7 days after intervention start (t_2), after 28 days (t_3), and after 3 months (end of intervention; t_4). These visits included the collection of a blood sample, saliva and stool samples, a clinical interview, a 24-hour heart rate variability measurement, and several questionnaires assessing psychological and cognitive measures, sleep quality as well as dietary intake measured by a food frequency questionnaire, the Vienna Food Record (VFR; see 2.4). In this study, we only analyzed dietary intake using the VFR.

The study was registered on clinicaltrials.gov (NCT-04772664) on August 16, 2021, and received ethical approval (EK-No: 33–227 ex 20/21). All participants provided written informed consent.

Probiotic intervention

Participants in the probiotic group received a multispecies probiotic (OMNi-BiOTiC® STRESS Repair) from Allergosan® (Graz, Austria) for a period of three months. They consumed one sachet (3g) twice daily, providing a total of 1.5×10^{10} CFU. This probiotic contained nine bacterial species: *Bifidobacterium bifidum* W23, *Bifidobacterium lactis* W51 and W52, *Lactobacillus acidophilus* W22, *Lactobacillus casei* W56, *Lactobacillus paracasei* W20, *Lactobacillus plantarum* W62, *Lactobacillus salivarius* W24, and *Lactococcus lactis* W19 with at least 7.5 billion microorganisms per sachet. These species were selected for their anti-inflammatory properties [73], their ability to reduce cognitive reactivity to sad mood [74] and their potential to activate the vagus nerve, as demonstrated in animal models [75–78].

The placebo group received identical-looking sachets in color, consistency, and taste, containing maize starch, maltodextrin, inulin, potassium chloride, magnesium sulfate, fructooligosaccharides, amylases and manganese sulfate. The probiotic and placebo powders had to be mixed with water and consumed twice daily (morning and evening).

The study followed a double-blind design. Participants were instructed to adhere to the intervention, refrain from taking additional probiotics, and maintain their usual diet, lifestyle and physical activity. Patients with *MD* continued their standard psychopharmacological treatment and usual care.

Questionnaires

General clinical and demographic data of participants (age, weight, height, BMI, sex, smoking, medication) were assessed. At all four time points, standardized questionnaires were administered.

The Vienna Food Record (VFR) was administered at all four study visits to document the participants' dietary intake within the past 24 hours. The VFR is a validated, paper-based, pre-coded dietary record specifically developed for Austrian adults, comprising 182 predefined food items representative of typical national dietary habits. It includes a brief instruction page and portion size illustrations (e.g., standard weights for common foods such as bread, meat or beverages), allowing participants to estimate quantities without professional assistance. Food consumption is recorded in predefined categories, including main meals, snacks and beverages with the option to note preparation details and consumption outside the home. [79]. In our study, a 24-h dietary record was evaluated at each visit. This approach was chosen to minimize participant burden and to account for the limited cognitive performance and resilience often present in *MD patients*. Given the additional completion of questionnaires within the study protocol, a higher workload was expected to markedly reduce compliance. Restricting the assessment to one day per visit was therefore considered the most feasible approach to ensure reliable data collection.

Other questionnaires included the Beck Depression Inventory (BDI) [80], which is a standardized instrument for self-assessment of the severity of depressive symptoms and the Hamilton Scale (HAMD) [81] – a clinical scale for evaluating depression severity. These questionnaires were administered to assess symptom-changes over time; all patients were included in the study regardless of depression severity (mild, moderate, or severe).

Furthermore, participants were asked to retrospectively assess their adherence to the daily probiotic/placebo intake over the three-month period using a questionnaire, in which they could choose from five predefined response categories: 0 = Not at all, 1 = Rarely, 2 = Mostly, 3 = Almost always, and 4 = Always.

Data analysis

To analyze the data obtained from the Vienna Food Record, the nutritional software nut.s® (v1 33.20, dato.denkwerkzeuge, Vienna) was used [82,83]. The software allows to calculate the nutritional values of different foods and recipes and to evaluate a person's nutritional status. Its database is based on the German Food Composition Database (Bundeslebensmittelschlüssel, BLS) and the Austrian Food Composition Database (Österreichische Nährwerttabelle, ÖNWT). For further analysis, the following dietary intake parameters were selected: carbohydrates [g], proteins [g], total fats [g], energy [kcal], omega-3 fatty acids [mg], omega-6 fatty acids [mg], saturated fatty acids [mg], vitamin B6 [mg], vitamin B12 [µg], vitamin D [µg], iron [mg], magnesium [mg], folic acid [mg], and dietary fiber [g]. These nutrients were chosen due to their relevance for neurotransmitter synthesis, general health, microbiome interactions and their specific role in psychiatric disorders, particularly depression [84].

Additionally, dietary variety (the number of different individual foods consumed) and dietary diversity (the number of different food groups represented in the diet) were assessed.

Notably, this analysis did not take into account the intake of any food supplements reported in the dietary protocol.

Statistical analysis

For the statistical analysis, IBM SPSS Statistics for Windows (Version 29.0. Armonk, NY: IBM Corp.) was used.

Sample size, randomization, and blinding. This analysis was conducted within the framework of the *ProBioHRV* trial, which investigated the effects of a multi-species probiotic (OMNi-BiOTiC® STRESS Repair) on vagus nerve function, gut microbiota composition, and related clinical outcomes in patients with major depression (MD) and healthy controls (HC). The original trial included 86 participants (43 MD, 43 HC). For the present study, dietary data were available from 53 participants (23 MD, 30 HC), who were therefore included in this sub-analysis.

Sample size determination. The planned total sample size of 80 participants (20 per group; HC: probiotic/placebo and MD: probiotic/placebo) was calculated using the Repeated Measures ANOVA (within–between interaction) procedure in G*Power (version 3.1).

Assumptions included a small effect size ($f=0.2$), $\alpha=0.05$, and power=0.95, ensuring adequate sensitivity to detect time $\times$ group $\times$ intervention interactions. Recruitment yielded 86 participants, exceeding the calculated requirement; however, only those with complete dietary data ($n=53$) were analyzed here.

Randomization and allocation concealment. Randomization was performed by the manufacturer of the probiotic and placebo using block randomization via www.randomization.com. The random allocation sequence was generated by a single staff member at the manufacturing site who was not otherwise involved in the study. Randomization was performed separately within each diagnostic group. The initial sample comprised 86 participants (43 with MD and 43 healthy controls), who were randomly assigned within group to either the probiotic or placebo intervention. This resulted in 20 participants with MD and 23 healthy controls for each intervention group. Reported subgroup sizes reflect the final sample after participant drop-out due to incomplete dietary assessment (see [Table 1](#)).

To maintain allocation concealment, the manufacturer prepared sequentially numbered, opaque, sealed packages according to the randomization list. Each participant received three packages, one for each month of treatment, labeled solely with the participant identification code. The probiotic and placebo products were identical in appearance, color, weight, smell, and taste, ensuring indistinguishability.

Blinding. Both the person responsible for randomization and all unblinded manufacturer personnel were sworn to confidentiality. All other members of the study team – including investigators, clinicians, participants, assessors, and data analysts – remained fully blinded until the database was locked after study completion.

Handling of missing data. No imputation was performed for missing data, as complete dietary and clinical datasets were available for all 53 participants included in the present analysis.

Descriptive statistics. Descriptive statistics were calculated to summarize baseline characteristics, including means and standard deviations for continuous variables, as well as absolute and relative frequencies for categorical variables.

Inferential statistics. To assess the comparability of the groups at baseline, all demographic and clinical variables were subjected to appropriate statistical testing. Categorical variables such as sex and smoking status were analyzed using Chi-square tests; in cases of low expected cell counts, the Fisher's exact test was applied. Continuous variables, including age, height, weight, BMI, as well as the psychometric scores BDI and HAMD, were first tested for normality using the Shapiro–Wilk test. Depending on the distribution, either independent samples t-tests (for normally distributed data) or Mann–Whitney U tests (for non-normally distributed data) were used to compare the groups. This approach ensured that baseline differences were appropriately accounted for in the subsequent analyses.

Potential differences in participant adherence between intervention and diagnosis groups were compared using Mann–Whitney–U tests.

To analyze changes in the participants' dietary nutrient intake for each parameter, mixed analyses of variance (ANOVA) for repeated measures were used. The analysis included the within-subjects factor *time*, corresponding to the four measurement time points ($t1$ – $t4$), and the between-subjects factors *intervention* (*placebo* vs. *probiotic group*) and *diagnosis* (*MD*, *HC*). In addition, post hoc analyses were performed to elucidate group differences. Post-hoc comparisons within each ANOVA were Bonferroni-corrected; however, we did not adjust for the number of ANOVAs, as corrections across conceptually distinct analyses are not recommended since they may inflate Type II error [85].

To verify that the assumptions required for conducting ANOVA were met, we assessed data sphericity using Mauchly's test, and homogeneity of variances using Levene's test.

Normality was assessed by examining the unstandardized residuals using the Shapiro–Wilk test. Data for carbohydrates [g], proteins [g], total fats [g], energy [kcal], and saturated fatty acids [mg] followed a normal distribution (all $p > .05$). Variables that showed substantial deviations from normality, defined as significant Shapiro–Wilk results ($p < .05$) in at least 50% of the groups, were log-transformed to meet the assumptions of parametric testing (they all showed a right-skewed distribution). These included vitamin D [μg], folic acid [μg], fiber [g], variety, omega-3 fatty acids [mg], omega-6 fatty acids [mg], vitamin B6 [mg], vitamin B12 [μg], and iron [mg]. After log-transformation, Shapiro Wilk tests confirmed normal distribution of the data (all $p > .05$).

To rule out a potential attrition bias, we further conducted a drop-out analysis, comparing included individuals and individuals excluded due to incomplete dietary records in demographic parameters and depressive symptom severity at baseline (height, weight, BMI, depressive symptoms measured by HAMD, depressive symptoms measured by BDI, age, smoking status, diagnosis, and distribution of sex). We tested group differences using independent samples t-tests and Mann-Whitney-U tests and Chi square tests, depending on scale level and variable distribution.

Results

Descriptive data

The total sample comprised 53 participants, including 28 individuals in the placebo group and 25 in the probiotic group. Of these, 30 were *HC* and 23 had been diagnosed with *MD*. The mean age of participants was 36.68 years ($SD = 13.77$), and the sample included 39 women (73.6%) and 14 men (26.4%).

Group differences

Inferential analyses revealed no significant differences in sex, age, height, weight, or smoking status between the *probiotic* and *placebo* groups, between participants with *MD* and *HC* and between the *probiotic* and *placebo* groups when comparing *MD* and *HC*. As expected, baseline comparisons showed significant differences in BDI and HAMD scores between *MD* and *HC* participants – both overall and within the *probiotic* and *placebo* subgroups. However, no significant differences in these psychological measures were observed between the *probiotic* and *placebo* groups. [Table 1](#) provides a summary of these results.

Adherence

Mann-Whitney-U tests revealed a significant difference in subjective adherence in the *intervention* group ($Z = -2.28$, $p = .024$), with individuals taking probiotics showing higher adherence. There was no significant difference in the *diagnosis* group in their subjective adherence ($Z = -1.50$, $p = .142$).

ANOVA results

There were no significant violations of sphericity or homogeneity of variances between our groups, as tested using Mauchly's test and Levene's test in most nutrients, respectively (all $p > .05$). For vitamin D, sphericity was violated and therefore the Greenhouse-Geisser corrected values are presented.

After log-transformation, data did not differ significantly from a normal distribution (all $p > .05$).

As the results obtained from log-transformed and untransformed data were highly comparable, we report the results based on the untransformed data for greater clarity and ease of interpretation.

Baseline comparability between groups (*placebo* vs. *probiotic*; *MD* vs. *HC*) was assessed using post-hoc pairwise comparisons of respective groups at *t1*. No significant differences were observed between any of the groups at *t1* with respect

to vitamin D, fiber intake, and dietary diversity (all $p > .05$). However, participants in *MD* and *HC* differed significantly in folic acid intake at t_1 , with *HC* showing higher values than *MD* ($p = .029$). Moreover, intervention groups differed in their dietary variety at t_1 ($p = .034$), with *placebo* group showing a significantly higher variety than *probiotics* group.

Main results. We found no significant differences between groups (*intervention*, *diagnosis*) and time points in the following nutrients: carbohydrates [g], proteins [g], total fats [g], energy [kcal], saturated fatty acids [mg], omega-3 fatty acids [mg], omega-6 fatty acids [mg], vitamin B6 [mg], vitamin B12 [μ g], iron [mg], and magnesium [mg], all $p > .05$.

Vitamin D. We found no significant main effect *time* ($p = .063$), *intervention* ($p = .434$), or *diagnosis* ($p = .278$), and no significant interactions between the factor pairs (all $p > .157$). However, we observed a significant interaction between *time* $\times$ *intervention* $\times$ *diagnosis* ($F(2.33, 113.99) = 4.51$, $p = .009$, $\eta_p^2 = .08$). The results revealed a differentiated, time-dependent pattern of effects (see Fig 2A).

Among *HC*, we found a significant difference between intervention conditions at t_2 , with individuals in the *probiotic* group showing significantly higher values in vitamin D intake compared to those in the *placebo* group ($p = .023$).




Fig 2. Average nutrition values for the four groups over time. A) Vitamin D, B) Folic acid, C) Dietary variety, and D) Diversity. Note. Error bars show the standard error. Asterisks show significant Bonferroni-corrected pairwise comparisons between *HC* (black) and *MC* (gray) groups; + represents a trend towards significance.

<https://doi.org/10.1371/journal.pone.0350801.g002>

In the *MD* group, a similar trend emerged at *t4*, with higher values under *probiotic* treatment than under *placebo*, although this difference did not reach significance ($p = .058$).

Comparisons between *MD* and *HC* within each intervention condition revealed that under *probiotic* treatment, *MD* had significantly lower values than *HC* at *t2* ($p = .036$). Under *placebo*, a similar group difference was observed at *t4*, but did not reach statistical significance ($p = .062$).

Folic acid. Our data showed no significant effect of *time* ($p = .199$), or *intervention* ($p = .220$), but a significant effect for *diagnosis* ($F(1, 48) = 6.56$, $p = .014$, $\eta_p^2 = .12$), suggesting that *HC* had a higher intake of folic acid than patients with *MD* over all four time points. There were no significant interactions between factor pairs (all $p > .158$) or between *time x intervention x diagnosis* ($p = .219$), see [Fig 2B](#).

Fiber. We observed a significant main effect of *time* ($F(3, 147) = 3.38$, $p = .020$, $\eta_p^2 = .06$), but no significant differences for *intervention* ($p = .237$) and *diagnosis* ($p = .203$). Moreover, there were no significant effects for interactions between factor pairs (all $p > .169$) or the interaction *time x intervention x diagnosis* ($p = .290$). These findings indicate a significant decrease in fiber intake between *t1* and *t2*, independent of groups.

Variety. We found a significant effect *time* ($F(3, 147) = 6.44$, $p < .001$, $\eta_p^2 = .12$) and *intervention* ($F(1, 49) = 5.22$, $p = .027$, $\eta_p^2 = .10$), but no effect *diagnosis* ($p = .300$) or between the factor pairs (all $p > .611$). Our data also showed a significant interaction *time x intervention x diagnosis* ($F(3, 147) = 4.63$, $p = .004$, $\eta_p^2 = .09$), see [Fig 2C](#).

In the *MD* group, participants receiving *placebo* reported significantly higher scores in their dietary variety at *t1* compared to those receiving the *probiotic* ($p = .041$).

In the *HC* group, significant differences between intervention conditions were found at *t2* and *t4*, with the *placebo* group again showing higher values than the *probiotic* group ($p = .016$ and $p = .031$, respectively).

These results suggest that across groups and most time points, the *probiotic* intervention was associated with lower outcome scores.

Diversity. Our data showed no significant effect for *time* ($p = .343$), *intervention* ($p = .097$), or *diagnosis* ($p = .439$) and no significant interaction between factor pairs (all $p > .632$). We found a significant interaction between *time x interaction x diagnosis* ($F(3, 147) = 5.16$, $p = .002$, $\eta_p^2 = .10$), see [Fig 2D](#).

Post-hoc comparisons revealed that, within the *MD* group, participants receiving *placebo* had significantly higher diversity scores than those receiving *probiotics* at time point 3 ($p = .030$). No other time points in this group showed statistically significant differences.

These results indicate that probiotic supplementation may have led to lower scores specifically in the *MD* group at time point 3, with no such effects observed in the *HC* group.

Drop-out analysis. Chi-square tests of independence showed no significant association between diagnostic group and study inclusion ($\chi^2(1) = .54$, $p = .463$, $\phi = .079$), between smoking status and study inclusion ($\chi^2(1) = 1.49$, $p = .222$, $\phi = .132$), and sex and study inclusion ($\chi^2(1) = 1.59$, $p = .207$, $\phi = .136$). All expected cell frequencies met the assumptions for the test. Independent-samples t-tests between included and excluded participants showed no significant differences for height, $t(84) = .20$, $p = .840$; depressive symptoms measured by the HAMD, $t(82) = .02$, $p = .987$, or depressive symptoms measured by the BDI, $t(79) = -.81$, $p = .420$. Mann–Whitney–U tests further indicated no significant differences between included and excluded participants in age ($U = 798.00$, $Z = -.68$, $p = .500$), BMI ($U = 748.00$, $Z = -1.12$, $p = .264$), or weight ($U = 700.50$, $Z = -1.34$, $p = .183$).

The drop-out analysis indicated that included and excluded participants did not differ significantly in any of the examined variables.

Discussion

Summary of findings

The present study aimed to determine whether daily supplementation with probiotics over a three-month period influences dietary intake patterns in participants with *MD* and *HC*. Sixteen predefined nutritional parameters were analyzed to assess

potential group differences and temporal patterns. The probiotic intervention did not result in consistent changes in macro- or micronutrient intake. Instead, exploratory time- and group-dependent patterns emerged for selected measures, including vitamin D, folic acid, fiber, and dietary variety and diversity. Overall, the findings indicate that potential probiotic-associated effects on dietary intake in this sample were relatively small, heterogeneous, and context dependent and should be interpreted cautiously as hypothesis-generating rather than confirmatory.

Vitamin D

Vitamin D intake showed an exploratory three-way interaction (*time × diagnosis × intervention*). Among HC, probiotic supplementation was associated with significantly higher vitamin D intake at one week after intervention start (t2) compared to placebo; however, this difference was primarily driven by a marked decrease in the HC placebo group, while intake in the HC probiotic group remained relatively stable across time. In contrast, participants with major depression (MD) showed a delayed pattern: vitamin D intake in the probiotic group increased steadily throughout the study, culminating in higher intake after the three-month intervention (t4) compared to the MD placebo group. Notably, this difference reached only trend-level significance ($p = .058$) and was not consistent across groups and time points. Taken together, these findings suggest a possible diagnosis- and time-dependent pattern, but should be interpreted with caution given their conditional nature and limited robustness.

One possible, albeit speculative, explanation is that probiotic supplementation may indirectly influence dietary behavior via gut–brain axis pathways affecting mood, motivation, and appetite regulation [86–88]. Such mechanisms could be particularly relevant in depression, where reduced motivation and suboptimal dietary patterns may limit nutrient intake, although direct evidence for this pathway is currently lacking since the present study did not assess appetite, food motivation, gastrointestinal symptoms, vitamin D status, or microbiome composition directly.

Given the small subgroup sizes, these patterns should be interpreted with caution and should be viewed as descriptive trends intended to inform future studies rather than evidence of a reliable intervention effect. In particular, future well-powered trials should combine microbiome profiling, validated measures of appetite and food preferences, and biomarker-based vitamin D assessments over extended follow-up periods to confirm whether probiotic supplementation can support sustained improvements in vitamin D intake and status, particularly in individuals with major depression.

Folic acid

Folic acid intake was consistently lower in MD compared to HC across all time points, independent of intervention. Notably, the two groups (HC, MD) already showed significant differences at baseline. This observation is consistent with prior findings linking depression to suboptimal nutritional status, including deficiencies in B vitamins such as folate [89–91]. Folate plays a critical role in one-carbon metabolism and methylation pathways, acting as an essential cofactor for the conversion of homocysteine to methionine and for the synthesis of S-adenosylmethionine (SAM), the universal methyl donor involved in DNA, RNA, neurotransmitter, and phospholipid methylation. Impaired methylation capacity has been implicated in the pathophysiology of depression, as it can disrupt monoamine neurotransmitter synthesis and gene expression relevant to mood regulation. In this context, the use of bioactive L-methylfolate as an adjunctive treatment in depression has been recommended in the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines on nutraceuticals and phytochemicals for depression [60]; particularly in individuals with low folate status or genetic variants affecting folate metabolism (e.g., MTHFR polymorphisms) [91,92].

Fiber

Fiber intake declined significantly after one week (t2), regardless of *intervention* or *diagnosis*. These findings may reflect short-term reactivity to study procedures (e.g., dietary recording or stress from HRV monitoring), rather than intervention effects.

Dietary variety

Dietary variety also showed an exploratory three-way interaction (*time × diagnosis × intervention*). In healthy controls, higher variety scores were observed in the *placebo* group at selected time points (*t2*, *t4*) compared to the *probiotic* group, suggesting a potential reduction in dietary variety due to probiotic supplementation. In the depressed group, participants receiving the placebo reported significantly higher variety scores at time point *t1* compared to those in the probiotic group. However, since baseline comparisons already showed significant differences between intervention groups prior to the start of the intervention, with the *placebo* group reporting higher variety than the *probiotic* group, group effects may not be attributable to the intervention itself.

Regarding dietary variety and diversity, both indicators of overall diet quality, our results consistently showed lower scores in the *probiotic* group at certain time points. This pattern cannot be explained by a clear underlying mechanism based on the present data. One possible interpretation is that these findings reflect subtle behavioral changes rather than direct effects on nutrient intake per se. For example, participants may have relied on a narrowing of dietary choices during probiotic supplementation, potentially influenced by factors such as perceived gastrointestinal effects, routine stabilization, or changes in food-related decision-making. However, these interpretations remain speculative and cannot be directly tested within the current study design.

A reduction in dietary variety and diversity has previously been associated with a shift in gut microbiota composition induced by the intake of live microorganisms [93]. Although microbiome data were not included in the present analysis, findings from the parent trial [69] provide relevant contextual information. In that study, probiotic supplementation was associated with functional changes, such as altered vagal nerve activity, despite the absence of significant changes in overall microbial diversity. This dissociation between functional effects and compositional stability suggests that probiotic effects may not necessarily be reflected in global diversity measures, but may instead operate through more subtle functional or signaling pathways. In this context, the observed changes in dietary variety and diversity may reflect indirect behavioral modulation rather than direct microbiome restructuring. It is conceivable that the altered microbiome required a less diverse external nutrient input, which may have contributed to a decline in these measures.

Given the exploratory nature of these findings, the small sample size, and the presence of baseline imbalances, the observed patterns should be interpreted with caution.

Future studies integrating microbiome profiling, appetite and food preference assessments and objective diet quality measures should replicate and extend these findings by clarifying the mechanisms underlying this pattern.

Adherence

Participants receiving probiotics reported significantly higher subjective adherence than those receiving placebo, despite the blinded study design. This could raise concerns about potential unblinding. However, several factors argue against systematic unblinding. Both probiotic and placebo sachets were identical in appearance, consistency, taste, and mode of administration, and no participant reported awareness of group allocation. The observed difference may therefore reflect subtle differences in perceived tolerability, gastrointestinal comfort, or general well-being that may have influenced motivation for consistent intake without necessarily revealing group assignment. Alternatively, nonspecific factors such as random variation in motivation, perceived well-being, or daily routines may have contributed to the difference. The absence of adherence differences between MD and HC participants further suggests that diagnosis did not systematically influence compliance.

Limitations

Several limitations and potential sources of bias should be considered when interpreting the findings of this pilot study. The primary limitation is the assessment of dietary intake for which we used a self-report food record, which can be inherently susceptible to

recall errors and social desirability bias. Specifically, participants may have underreported or misreported their consumption due to recall difficulties or discomfort about disclosing certain eating patterns. Moreover, although the Vienna Food Record is a validated prospective instrument typically applied over multiple days to approximate habitual intake, dietary assessment in the present study was restricted to a single 24-hour record at each time point. This decision was driven by feasibility considerations in a clinically vulnerable population with major depressive disorder, where multi-day dietary recording is often associated with reduced adherence due to symptom-related burden (e.g., impaired concentration and motivation). To reduce drop-out, dietary assessment was therefore restricted to one day in close temporal proximity to biological sampling. While this represents a pragmatic compromise, it precludes conclusions about habitual intake and should be considered a methodological learning point for future studies.

Although microbiome data were not included in the present analysis, results from the parent trial [69] provide important contextual information. Notably, probiotic supplementation was associated with functional changes, such as altered vagal nerve activity, despite the absence of significant changes in overall microbial diversity. This dissociation between functional effects and compositional stability suggests that probiotic effects may not necessarily be reflected in global diversity measures. However, as microbiome data were not linked to dietary outcomes in the present analysis, these interpretations remain speculative and require confirmation in future studies integrating microbiome, behavioral, and nutritional data. In addition, no objective mechanistic measures (e.g., appetite-regulating hormones, neural or behavioral endpoints) were included. Consequently, the study does not allow conclusions regarding the biological pathways underlying the observed changes in dietary behavior. A key limitation is that the relatively small sample size ($N=53$) substantially limited statistical power and generalizability. This constraint is especially critical for subgroup and interaction analyses, which are highly susceptible to spurious findings in small samples and should therefore be regarded as exploratory. The limited power may also have precluded detection of small to moderate effects. For example, the observed increase in vitamin D intake in the probiotic group among participants with major depression at $t4$ did not reach statistical significance ($p=.058$), despite mirroring patterns seen in healthy controls at earlier time points.

In addition, only four time points were used to assess dietary intake, including baseline and three follow-ups during the intervention period. While this design balances data resolution with participant burden, it may have missed finer fluctuations in dietary patterns and, more importantly, long-term effects, especially with nutrients like vitamin D. Thus, the intervention period of three months provides only a limited view of longer-term changes in dietary patterns and gut microbiota composition. Extending the observation period or including post-intervention follow-up assessments could offer a clearer picture of the stability and persistence of any observed changes.

Baseline differences between groups in certain dietary variables (i.e., folic acid intake and dietary variety) represent an additional limitation. Such imbalances may influence the interpretation of observed changes, as differences at later time points could partly reflect pre-existing group differences rather than intervention effects. Although the applied statistical models account for within-subject changes over time, residual confounding due to baseline variability cannot be ruled out. Another factor to consider is the Hawthorne effect, as participants' awareness of being part of a study may have influenced their dietary choices, consciously or unconsciously [94]. While this effect is difficult to quantify, it may have led to temporary behavior changes that do not reflect long-term habits.

Finally, dietary supplement use of participants was not assessed. This could have introduced unmeasured variability in nutrient intake and confounded intervention effects.

Taken together, these limitations underscore that the present findings should be interpreted as descriptive and hypothesis-generating rather than in an inferential manner. They also highlight important methodological considerations for future, adequately powered trials, including improved control of baseline differences, repeated dietary assessments of habitual intake, and the inclusion of objective biomarkers to test these hypotheses.

Conclusions

Although probiotics have been hypothesized to influence dietary behavior through gut–brain axis pathways, the absence of assessments of appetite-regulating hormones, neurotransmitters, neuroimaging, and microbiome composition in the

present study limits mechanistic interpretation of the observed changes in dietary variety and diversity. While findings from the parent trial [69] suggest that probiotic supplementation induce functional changes (e.g., altered vagal nerve activity) without detectable alterations in overall microbial diversity, the present results should be regarded as exploratory and hypothesis-generating rather than as evidence of a confirmed biological effect.

In summary, while probiotic supplementation did not lead to consistent changes in nutrient intake across all participants, exploratory, group-specific, and time-dependent patterns were observed for selected parameters – including vitamin D intake as well as dietary variety and diversity. Given the pilot nature of the study, baseline differences between groups, reliance on self-reported dietary data, and limited statistical power, these patterns should be interpreted as descriptive and indicative rather than as evidence of causal intervention effects. Future research should replicate and extend these preliminary results in larger, adequately powered samples. Such studies should integrate objective biomarkers of nutrient status, systematic assessment of supplement use, and comprehensive microbiome profiling to elucidate whether and how specific probiotic formulations may meaningfully influence dietary behavior or nutrient status in clinical and non-clinical populations. Taken together, the present findings provide preliminary methodological and descriptive insights to guide the design of future investigations into the complex interplay between probiotics, diet, and mental health.

Supporting information

S1 File. 7_Abschlussbericht.

(PDF)

S2 File. 7_Final report.

(PDF)

S3 File. CONSORT_2025_editable_checklist_LGS.

(DOCX)

S4 File. EK_Protokoll_V1.2_03072021 en-GB 1.

(PDF)

S5 File. EK_Protokoll_V1.2_03072021.

(PDF)

S6 File. EK-Vote_till_2022-06-30.

(PDF)

S7 File. EK-Vote_till_2023_06_30.

(PDF)

S8 File. EK-Vote_till_2024-06-30.

(PDF)

S9 File. EK-Votum_bis_2022-06-30.

(PDF)

S10 File. EK-Votum_bis_2023-06-30.

(PDF)

S11 File. EK-Votum_bis_2024-06-30.

(PDF)

Acknowledgments

We gratefully acknowledge all our participants for their time and commitment, which made this investigation possible. We also thank Emma Wesener for proof-reading the manuscript!

Author contributions

Conceptualization: Sabrina Mörtl.

Data curation: Marilena Wilding, Martin Narrath, Daria Schlotmann, Marie-Therese Sallmutter, Jasmin Tatzer, Andreas Brandstätter, Julia Deborah Lang, Julian Wenninger, Lena Gruber, Andreas Baranyi, Sabrina Mörtl.

Formal analysis: Marilena Wilding, Julia Corinna Putz.

Funding acquisition: Sabrina Mörtl.

Supervision: Sonja Lackner, Sandra Holasek, Jolana Wagner-Skacel, Sabrina Mörtl.

Validation: Marilena Wilding.

Visualization: Marilena Wilding.

Writing – original draft: Marilena Wilding, Julia Corinna Putz.

Writing – review & editing: Marilena Wilding, Sonja Lackner, Andreas Brandstätter, Sandra Holasek, Mary I Butler, Susanne Bengesser, Andreas Baranyi, Jolana Wagner-Skacel, Sabrina Mörtl.

References

1. Haub C. How many people have ever lived on earth?. *Popul Today*. 1995;23(2):4–5.
2. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: Roles in cancer initiation, development and therapeutic efficacy. *Signal Transduct Target Ther*. 2023;8(1):35. <https://doi.org/10.1038/s41392-022-01304-4> PMID: 36646684
3. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014;505(7484):559–63. <https://doi.org/10.1038/nature12820> PMID: 24336217
4. Ballini A, Dipalma G, Isacco CG, Boccellino M, Di Domenico M, Santacroce L, et al. Oral microbiota and immune system crosstalk: A translational research. *Biology (Basel)*. 2020;9(6):131. <https://doi.org/10.3390/biology9060131> PMID: 32560235
5. Ghosh S, Pramanik S. Structural diversity, functional aspects and future therapeutic applications of human gut microbiome. *Arch Microbiol*. 2021;203(9):5281–308. <https://doi.org/10.1007/s00203-021-02516-y> PMID: 34405262
6. Isacco CG, Ballini A, De Vito D, Nguyen KCD, Cantore S, Bottalico L, et al. Rebalancing the oral microbiota as an efficient tool in endocrine, metabolic and immune disorders. *Endocr Metab Immune Disord Drug Targets*. 2021;21(5):777–84. <https://doi.org/10.2174/1871530320666200729142504> PMID: 32727337
7. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol*. 2015;21(29):8787–803.
8. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. *Nature*. 2007;449(7164):804–10. <https://doi.org/10.1038/nature06244> PMID: 17943116
9. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. *Science*. 2009;326(5960):1694–7. <https://doi.org/10.1126/science.1177486> PMID: 19892944
10. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature*. 2012;489(7415):220–30. <https://doi.org/10.1038/nature11550> PMID: 22972295
11. González-Rodríguez I, Ruiz L, Gueimonde M, Margolles A, Sánchez B. Factors involved in the colonization and survival of bifidobacteria in the gastrointestinal tract. *FEMS Microbiol Lett*. 2013;340(1):1–10. <https://doi.org/10.1111/1574-6968.12056> PMID: 23181549
12. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science*. 2011;334(6052):105–8. <https://doi.org/10.1126/science.1208344> PMID: 21885731
13. Koloverou E, Panagiotakos DB, Pitsavos C, Chrysoshoou C, Georgousopoulou EN, Grekas A. Adherence to Mediterranean diet and 10-year incidence (2002-2012) of diabetes: Correlations with inflammatory and oxidative stress biomarkers in the ATTICA cohort study. *Diabetes Metab Res Rev*. 2016;32(1):73–81.

14. Lopez-Legarrea P, Fuller NR, Zulet MA, Martinez JA, Caterson ID. The influence of Mediterranean, carbohydrate and high protein diets on gut microbiota composition in the treatment of obesity and associated inflammatory state. *Asia Pac J Clin Nutr*. 2014;23(3):360–8. <https://doi.org/10.6133/apjcn.2014.23.3.16> PMID: 25164445
15. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JL. The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med*. 2009;1(6):6ra14. <https://doi.org/10.1126/scitranslmed.3000322> PMID: 20368178
16. Reddy BS, Weisburger JH, Wynder EL. Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. *J Nutr*. 1975;105(7):878–84. <https://doi.org/10.1093/jn/105.7.878> PMID: 1138032
17. Drasar BS, Crowther JS, Goddard P, Hawksworth G, Hill MJ, Peach S, et al. The relation between diet and the gut microflora in man. *Proc Nutr Soc*. 1973;32(2):49–52. <https://doi.org/10.1079/pns19730014> PMID: 4791056
18. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut*. 2016;65(11):1812–21. <https://doi.org/10.1136/gutjnl-2015-309957> PMID: 26416813
19. Liu B-N, Liu X-T, Liang Z-H, Wang J-H. Gut microbiota in obesity. *World J Gastroenterol*. 2021;27(25):3837–50. <https://doi.org/10.3748/wjg.v27.i25.3837> PMID: 34321848
20. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JL. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A*. 2005;102(31):11070–5. <https://doi.org/10.1073/pnas.0504978102> PMID: 16033867
21. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JL. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444(7122):1027–31. <https://doi.org/10.1038/nature05414> PMID: 17183312
22. Indiani CMDSP, Rizzardi KF, Castelo PM, Ferraz LFC, Darrieux M, Parisotto TM. Childhood obesity and firmicutes/bacteroidetes ratio in the gut microbiota: A systematic review. *Child Obes*. 2018;14(8):501–9. <https://doi.org/10.1089/chi.2018.0040> PMID: 30183336
23. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, et al. Human gut microbiota in obesity and after gastric bypass. *Proc Natl Acad Sci U S A*. 2009;106(7):2365–70. <https://doi.org/10.1073/pnas.0812600106> PMID: 19164560
24. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun*. 2015;48:186–94. <https://doi.org/10.1016/j.bbi.2015.03.016> PMID: 25882912
25. Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, Cong XS. Altered composition of gut microbiota in depression: A systematic review. *Front Psychiatry*. 2020;11:541. <https://doi.org/10.3389/fpsy.2020.00541> PMID: 32587537
26. Limbana T, Khan F, Eskander N. Gut microbiome and depression: How microbes affect the way we think. *Cureus*. 2020;12(8):e9966.
27. Zimmermann-Rösner A, Prehn-Kristensen A. The microbiome in child and adolescent psychiatry. *Z Kinder Jugendpsychiatr Psychother*. 2024;52(4):213–26. <https://doi.org/10.1024/1422-4917/a000965> PMID: 38240707
28. Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. *J Transl Med*. 2017;15(1):73. <https://doi.org/10.1186/s12967-017-1175-y> PMID: 28388917
29. Han H, Yi B, Zhong R, Wang M, Zhang S, Ma J, et al. From gut microbiota to host appetite: Gut microbiota-derived metabolites as key regulators. *Microbiome*. 2021;9(1):162. <https://doi.org/10.1186/s40168-021-01093-y> PMID: 34284827
30. Banks WA. The blood-brain barrier as an endocrine tissue. *Nat Rev Endocrinol*. 2019;15(8):444–55. <https://doi.org/10.1038/s41574-019-0213-7> PMID: 31127254
31. Cedernaes J, Huang W, Ramsey KM, Waldeck N, Cheng L, Marcheva B, et al. Transcriptional Basis for rhythmic control of hunger and metabolism within the AgRP Neuron. *Cell Metab*. 2019;29(5):1078–1091.e5. <https://doi.org/10.1016/j.cmet.2019.01.023> PMID: 30827863
32. Eleftheriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. *Nature*. 2005;434(7032):514–20. <https://doi.org/10.1038/nature03398> PMID: 15724149
33. Kilpeläinen TO, Carli JFM, Skowronski AA, Sun Q, Kriebel J, Feitosa MF, et al. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. *Nat Commun*. 2016;7:10494. <https://doi.org/10.1038/ncomms10494> PMID: 26833098
34. Park S, Aintablian A, Coupe B, Bouret SG. The endoplasmic reticulum stress-autophagy pathway controls hypothalamic development and energy balance regulation in leptin-deficient neonates. *Nat Commun*. 2020;11(1):1914. <https://doi.org/10.1038/s41467-020-15624-y> PMID: 32313051
35. Rasmussen BA, Breen DM, Duca FA, Côté CD, Zadeh-Tahmasebi M, Filippi BM, et al. Jejunal leptin-PI3K signaling lowers glucose production. *Cell Metab*. 2014;19(1):155–61. <https://doi.org/10.1016/j.cmet.2013.11.014> PMID: 24361011
36. Sobhani I, Bado A, Vissuzaine C, Buyse M, Kermorgant S, Laigneau JP, et al. Leptin secretion and leptin receptor in the human stomach. *Gut*. 2000;47(2):178–83. <https://doi.org/10.1136/gut.47.2.178> PMID: 10896907
37. Xu J, Bartolome CL, Low CS, Yi X, Chien C-H, Wang P, et al. Genetic identification of leptin neural circuits in energy and glucose homeostases. *Nature*. 2018;556(7702):505–9. <https://doi.org/10.1038/s41586-018-0049-7> PMID: 29670283
38. Yang Y, van der Klaauw AA, Zhu L, Cacciottolo TM, He Y, Stadler LKJ, et al. Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis. *Nat Commun*. 2019;10(1):1718. <https://doi.org/10.1038/s41467-019-08737-6> PMID: 30979869
39. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500(7464):541–6. <https://doi.org/10.1038/nature12506> PMID: 23985870
40. Kuhnen P, Krude H, Biebermann H. Melanocortin-4 receptor signalling: Importance for weight regulation and obesity treatment. *Trends Mol Med*. 2019;25(2):136–48.

41. Panaro BL, Tough IR, Engelstoft MS, Matthews RT, Digby GJ, Møller CL, et al. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. *Cell Metab*. 2014;20(6):1018–29. <https://doi.org/10.1016/j.cmet.2014.10.004> PMID: [25453189](#)
42. Suarez AN, Liu CM, Cortella AM, Noble EE, Kanoski SE. Ghrelin and orexin interact to increase meal size through a descending hippocampus to hindbrain signaling pathway. *Biol Psychiatry*. 2020;87(11):1001–11. <https://doi.org/10.1016/j.biopsych.2019.10.012> PMID: [31836175](#)
43. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, et al. Ghrelin action in the brain controls adipocyte metabolism. *J Clin Invest*. 2006;116(7):1983–93. <https://doi.org/10.1172/JCI25811> PMID: [16767221](#)
44. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science*. 2013;341(6150):1241214. <https://doi.org/10.1126/science.1241214> PMID: [24009397](#)
45. Schéle E, Grahnmemo L, Anesten F, Hallén A, Bäckhed F, Jansson J-O. The gut microbiota reduces leptin sensitivity and the expression of the obesity-suppressing neuropeptides proglucagon (Gcg) and brain-derived neurotrophic factor (Bdnf) in the central nervous system. *Endocrinology*. 2013;154(10):3643–51. <https://doi.org/10.1210/en.2012-2151> PMID: [23892476](#)
46. Suárez-Zamorano N, Fabbiano S, Chevalier C, Stojanović O, Colin DJ, Stevanović A, et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. *Nat Med*. 2015;21(12):1497–501. <https://doi.org/10.1038/nm.3994> PMID: [26569380](#)
47. White PJ, Newgard CB. Branched-chain amino acids in disease. *Science*. 2019;363(6427):582–3. <https://doi.org/10.1126/science.aav0558> PMID: [30733403](#)
48. Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. *Nat Commun*. 2018;9(1):2872. <https://doi.org/10.1038/s41467-018-05336-9> PMID: [30030441](#)
49. Swartz TD, Duca FA, de Wouters T, Sakar Y, Covasa M. Up-regulation of intestinal type 1 taste receptor 3 and sodium glucose luminal transporter-1 expression and increased sucrose intake in mice lacking gut microbiota. *Br J Nutr*. 2012;107(5):621–30. <https://doi.org/10.1017/S0007114511003412> PMID: [21781379](#)
50. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. *Ann Nutr Metab*. 2012;61(2):160–74. <https://doi.org/10.1159/000342079> PMID: [23037511](#)
51. R F. Probiotics: The scientific basis. 2012.
52. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Nutrition*. 2016;32(3):315–20. <https://doi.org/10.1016/j.nut.2015.09.003> PMID: [26706022](#)
53. Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: A summary of the evidence. *Am Fam Physician*. 2017;96(3):170–8. PMID: [28762696](#)
54. Amirani E, Milajerdi A, Mirzaei H, Jamilian H, Mansournia MA, Hallajzadeh J, et al. The effects of probiotic supplementation on mental health, biomarkers of inflammation and oxidative stress in patients with psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials. *Complement Ther Med*. 2020;49:102361. <https://doi.org/10.1016/j.ctim.2020.102361> PMID: [32147043](#)
55. Chao L, Liu C, Sutthawongwadee S, Li Y, Lv W, Chen W, et al. Effects of probiotics on depressive or anxiety variables in healthy participants under stress conditions or with a depressive or anxiety diagnosis: A meta-analysis of randomized controlled trials. *Front Neurol*. 2020;11:421. <https://doi.org/10.3389/fneur.2020.00421> PMID: [32528399](#)
56. Dehghani F, Abdollahi S, Shidfar F, Clark CCT, Soltani S. Probiotics supplementation and brain-derived neurotrophic factor (BDNF): A systematic review and meta-analysis of randomized controlled trials. *Nutr Neurosci*. 2023;26(10):942–52. <https://doi.org/10.1080/1028415X.2022.2110664> PMID: [35996352](#)
57. Goh KK, Liu Y-W, Kuo P-H, Chung Y-CE, Lu M-L, Chen C-H. Effect of probiotics on depressive symptoms: A meta-analysis of human studies. *Psychiatry Res*. 2019;282:112568. <https://doi.org/10.1016/j.psychres.2019.112568> PMID: [31563280](#)
58. Mörl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the Microbiota-Gut-Brain Axis: Focus on Psychiatry. *Curr Nutr Rep*. 2020;9(3):171–82. <https://doi.org/10.1007/s13668-020-00313-5> PMID: [32406013](#)
59. O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav Brain Res*. 2015;277:32–48. <https://doi.org/10.1016/j.bbr.2014.07.027> PMID: [25078296](#)
60. Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry*. 2022;23(6):424–55. <https://doi.org/10.1080/15622975.2021.2013041> PMID: [35311615](#)
61. Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, et al. Gut microbiota and obesity: A role for probiotics. *Nutrients*. 2019;11(11):2690. <https://doi.org/10.3390/nu11112690> PMID: [31703257](#)
62. Ahn HY, Kim M, Chae JS, Ahn Y-T, Sim J-H, Choi I-D, et al. Supplementation with two probiotic strains, *Lactobacillus curvatus* HY7601 and *Lactobacillus plantarum* KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. *Atherosclerosis*. 2015;241(2):649–56. <https://doi.org/10.1016/j.atherosclerosis.2015.06.030> PMID: [26117402](#)
63. Cani PD, Dewever C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. *Br J Nutr*. 2004;92(3):521–6. <https://doi.org/10.1079/bjn20041225> PMID: [15469657](#)

64. Gomes AC, de Sousa RGM, Botelho PB, Gomes TLN, Prada PO, Mota JF. The additional effects of a probiotic mix on abdominal adiposity and antioxidant Status: A double-blind, randomized trial. *Obesity* (Silver Spring). 2017;25(1):30–8. <https://doi.org/10.1002/oby.21671> PMID: 28008750
65. Higashikawa F, Noda M, Awaya T, Danshiitsoodol N, Matoba Y, Kumagai T, et al. Antiobesity effect of *Pediococcus pentosaceus* LP28 on overweight subjects: A randomized, double-blind, placebo-controlled clinical trial. *Eur J Clin Nutr*. 2016;70(5):582–7. <https://doi.org/10.1038/ejcn.2016.17> PMID: 26956126
66. Kim J, Yun JM, Kim MK, Kwon O, Cho B. *Lactobacillus gasseri* BNR17 supplementation reduces the visceral fat accumulation and waist circumference in obese adults: A randomized, double-blind, placebo-controlled trial. *J Med Food*. 2018;21(5):454–61. <https://doi.org/10.1089/jmf.2017.3937> PMID: 29688793
67. Minami J, Iwabuchi N, Tanaka M, Yamauchi K, Xiao J-Z, Abe F, et al. Effects of *Bifidobacterium breve* B-3 on body fat reductions in pre-obese adults: A randomized, double-blind, placebo-controlled trial. *Biosci Microbiota Food Health*. 2018;37(3):67–75. <https://doi.org/10.12938/bmfh.18-001> PMID: 30094122
68. Pedret A, Valls RM, Calderón-Pérez L, Llauredó E, Companys J, Pla-Pagà L, et al. Effects of daily consumption of the probiotic *Bifidobacterium animalis* subsp. *lactis* CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: A randomized controlled trial. *Int J Obes (Lond)*. 2019;43(9):1863–8. <https://doi.org/10.1038/s41366-018-0220-0> PMID: 30262813
69. Mörl S, Narrath M, Schlotmann D, Sallmutter M-T, Putz J, Lang J, et al. Multi-species probiotic supplement enhances vagal nerve function - results of a randomized controlled trial in patients with depression and healthy controls. *Gut Microbes*. 2025;17(1):2492377. <https://doi.org/10.1080/19490976.2025.2492377> PMID: 40298641
70. Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The effects of dietary improvement on symptoms of depression and anxiety: A meta-analysis of randomized controlled trials. *Psychosom Med*. 2019;81(3):265–80. <https://doi.org/10.1097/PSY.0000000000000673> PMID: 30720698
71. Mörl S, Wagner-Skacel J, Lahousen T, Lackner S, Holasek SJ, Bengesser SA, et al. The role of nutrition and the gut-brain axis in psychiatry: A review of the literature. *Neuropsychobiology*. 2018;:1–9. <https://doi.org/10.1159/000492834> PMID: 30223263
72. Organization WH. International Statistical Classification of Diseases and Related Health Problems. 10th Revision (ICD-10). 10 ed. Geneva: World Health Organization. 2019.
73. Reiter A, Bengesser SA, Hauschild A-C, Birk-Töglhofer A-M, Fellendorf FT, Platzer M, et al. Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder-Preliminary Results of the PROVIT Study. *Nutrients*. 2020;12(9):2575. <https://doi.org/10.3390/nu12092575> PMID: 32858844
74. Reininghaus EZ, Wetzlmair L-C, Fellendorf FT, Platzer M, Queissner R, Birner A, et al. Probiotic treatment in individuals with euthymic bipolar disorder: A pilot-study on clinical changes and compliance. *Neuropsychobiology*. 2020;79(1):71–9. <https://doi.org/10.1159/000493867> PMID: 30343291
75. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, et al. The anxiolytic effect of *Bifidobacterium longum* NCC3001 involves vagal pathways for gut-brain communication. *Neurogastroenterol Motil*. 2011;23(12):1132–9. <https://doi.org/10.1111/j.1365-2982.2011.01796.x> PMID: 21988661
76. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc Natl Acad Sci U S A*. 2011;108(38):16050–5. <https://doi.org/10.1073/pnas.1102999108> PMID: 21876150
77. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu X-N, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *J Physiol*. 2004;558(Pt 1):263–75. <https://doi.org/10.1113/jphysiol.2004.063388> PMID: 15133062
78. Tanida M, Yamano T, Maeda K, Okumura N, Fukushima Y, Nagai K. Effects of intraduodenal injection of *Lactobacillus johnsonii* La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. *Neurosci Lett*. 2005;389(2):109–14. <https://doi.org/10.1016/j.neulet.2005.07.036> PMID: 16118039
79. Putz P, Kogler B, Bersenkovitsch I. Reliability and validity of assessing energy and nutrient intake with the Vienna food record: a cross-over randomised study. *Nutr J*. 2019;18(1):7. <https://doi.org/10.1186/s12937-019-0431-9> PMID: 30691471
80. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. 2nd ed. San Antonio, TX: Psychological Corporation; 1996.
81. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960;23(1):56–62. <https://doi.org/10.1136/jnnp.23.1.56> PMID: 14399272
82. Denkwerkzeuge d. nut.s science. dato Denkwerkzeuge. 2024.
83. Ernährungsprotokoll W. <https://www.wiener-ernaehrungsprotokoll.at/>
84. Mader IM. Recovery from (treatment-resistant) depression after lifestyle changes and micronutrient precision supplementation: A preliminary field study in patients. *BMC Psychol*. 2023;11(1):229. <https://doi.org/10.1186/s40359-023-01263-7> PMID: 37568156
85. Rubin M. Inconsistent multiple testing corrections: The fallacy of using family-based error rates to make inferences about individual hypotheses. *Methods in Psychology*. 2024;10:100140. <https://doi.org/10.1016/j.metip.2024.100140>
86. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M. The Microbiota-Gut-Brain Axis. *Physiol Rev*. 2019;99(4):1877–2013.
87. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. *Lancet Gastroenterol Hepatol*. 2017;2(10):747–56. [https://doi.org/10.1016/S2468-1253\(17\)30147-4](https://doi.org/10.1016/S2468-1253(17)30147-4) PMID: 28844808

88. van de Wouw M, Schellekens H, Dinan TG, Cryan JF. Microbiota-gut-brain axis: Modulator of host metabolism and appetite. *J Nutr.* 2017;147(5):727–45. <https://doi.org/10.3945/jn.116.240481> PMID: [28356427](#)
89. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. *J Epidemiol Community Health.* 2007;61(7):631–7. <https://doi.org/10.1136/jech.2006.050385> PMID: [17568057](#)
90. Murakami K, Miyake Y, Sasaki S, Tanaka K, Arakawa M. Dietary folate, riboflavin, vitamin B-6, and vitamin B-12 and depressive symptoms in early adolescence: The Ryukyus Child Health Study. *Psychosom Med.* 2010;72(8):763–8. <https://doi.org/10.1097/PSY.0b013e3181f02f15> PMID: [20716710](#)
91. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry.* 2012;169(12):1267–74. <https://doi.org/10.1176/appi.ajp.2012.11071114> PMID: [23212058](#)
92. Stover PJ. Physiology of folate and vitamin B12 in health and disease. *Nutr Rev.* 2004;62(6 Pt 2):S3-12; discussion S13. <https://doi.org/10.1111/j.1753-4887.2004.tb00070.x> PMID: [15298442](#)
93. Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of probiotics on gut Microbiota: An overview. *Int J Mol Sci.* 2024;25(11):6022. <https://doi.org/10.3390/ijms25116022> PMID: [38892208](#)
94. Sedgwick P, Greenwood N. Understanding the Hawthorne effect. *BMJ.* 2015;351:h4672. <https://doi.org/10.1136/bmj.h4672> PMID: [26341898](#)